A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

NCT05266196 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Ewing Sarcoma
Myxoid Liposarcoma
Desmoplastic Small Round Cell Tumor
Extraskeletal Myxoid Chondrosarcoma
Angiomatoid Fibrous Histiocytoma
Clear Cell Sarcoma
Myoepithelial Tumor
Low Grade Fibromyxoid Sarcoma
Sclerosing Epithelioid Fibrosarcoma

Interventions

DRUG: Seclidemstat

Sponsor

Salarius Pharmaceuticals, LLC